SCHEMBL5651579

SCHEMBL5651579

CCOC(=O)c1sc2c(ccc(=O)n2-c2cccc(C#N)c2)c1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 3/20 0.49
FNTB P49356 3/20 0.49
ALDH1A1 P00352 7/20 0.41
MAPT P10636 4/20 0.41
HPGD P15428 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NOTUM Q6P988 1/20 0.40
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
SETD7 Q8WTS6 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ALOX15 P16050 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650036 0.94 FNTA (0.53) FNTAFNTBALDH1A1MAPTHPGD
SCHEMBL5652232 0.90 FNTA (0.49) FNTAFNTBALDH1A1MAPTHPGD
SCHEMBL5651739 0.88 ALDH1A1 (0.44) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5650136 0.87 MAPT (0.51) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5653063 0.87 ALDH1A1 (0.52) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5652382 0.86 DCTPP1 (0.43) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5648182 0.86 TRPM8 (0.45) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5650917 0.84 MAPT (0.46) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5653998 0.83 MAPT (0.48) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5650867 0.83 MAPT (0.47) ALDH1A1MAPTHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 FNTA 4164/4885FNTB 2145/4885ALDH1A1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.